



My GenomeWeb

[Business & Policy](#) [Technology](#) [Research](#) [Diagnostics](#) [Disease Areas](#) [Applied Markets](#) [Resources](#)

Enter your keywords

[Home](#) » [Business, Policy & Funding](#) » [Business News](#)

Viome Raises \$54M to Advance mRNA Platform for Diagnosis, Drug Development

Nov 10, 2021 | [staff reporter](#)[Save for later](#)

NEW YORK – Viome Life Sciences said Wednesday that it has raised \$54 million in pre-series C convertible funding with participation from existing and new investors. Added to prior funding, including a series B round in November 2019, the company said it has raised over \$125 million in total.

This latest influx will support expanded clinical research focused on aggressive cancers and chronic diseases, with an eventual goal of developing early-stage diagnostics and therapeutics using the firm's mRNA platform. Initially focused on direct-to-consumer, gut microbiome-based wellness testing, Viome has more recently [expanded its ambitions](#) to these broader areas.

Cancers in which the firm is researching its technology include pancreatic cancer, bile cancer, breast cancer, gastrointestinal cancers, gynecological cancers, and head, neck, and shoulder cancers. The company said it also has active therapeutics efforts in Alzheimer's, metabolic diseases, and mental health.

Viome and GlaxoSmithKline [recently announced](#) an agreement to expand a clinical validation partnership to develop new therapeutic interventions for select cancers and autoimmune diseases.

Returning investors in the pre-series C financing included Khosla Ventures, West River Group, Glico, Physician Partners, and Bold Capital Group. Ocgrow Ventures also participated as a new investor, and Viome said Harish Consul, Ocgrow's founder and CEO, will consequently serve as an observer on its board of directors.

Filed Under [+ Business News](#) [+ Molecular Diagnostics](#) [+ Cancer](#)

[+ Neurological & Psychological Disorders](#) [+ financing](#) [+ RNA-seq](#)

[+ North America](#)

We recommend

Startup Viome Raises \$15M in Series A Funding
[GenomeWeb, 2017](#)

'Fun, But'
[GenomeWeb, 2017](#)

Viome Forays Outside Molecularly Informed DTC Wellness Testing With Oral Cancer Assay | [Genomeweb](#)
[Molika Ashford, GenomeWeb](#)

Viome, Helomics Form Microbiome Analysis Partnership
[staff reporter, GenomeWeb, 2019](#)

Viome Shares First Details of DTC Microbiome Technology as Research Community Weighs Evidence
[GenomeWeb, 2019](#)

Startup Viome Raises \$15M in Series A Funding | [Genomeweb](#)
[staff reporter, GenomeWeb](#)

In Brief This Week: Ginkgo Bioworks, Novacyt, Viome, and More | [Genomeweb](#)
[staff reporter, GenomeWeb](#)

Viome Forays Outside Molecularly Informed DTC Wellness Testing With Oral Cancer Assay
[Molika Ashford, GenomeWeb, 2021](#)

Breaking News

- Quantum-Si Posts No Revenues in Q3 as Net Loss Doubles
- Cue Health Revenues up Massively in Q3
- 23andMe Fiscal Q2 Revenues Increase 7 Percent
- Israeli Government Extends CRISPR-IL Consortium With \$14.5M in New Funding
- HHS Provides \$650M to Support Point-of-Care MDx Tests for COVID-19
- Isoplexis Q3 Revenues Grow 28 Percent

the SCAN

Who Did What

According to the New York Times, Moderna and the US National Institutes of Health are clashing over who contributed to the invention of company's mRNA-based SARS-CoV-2 vaccine.

Seeking Boosters for All Adults

CNN reports Pfizer and BioNTech are pursuing US authorization for SARS-CoV-2 vaccine boosters for all adults.

Detected But Then?

New diagnostics may make it easier to diagnose dementia or Alzheimer's disease, but that may then strain healthcare systems, the Economist says.

Genome Biology Papers on RNA Sequence Variants, Sequencing Quality Control 2, Walnut Adaptation

In Genome Biology this week: pipeline to uncover RNA sequence variants, insights from the SEQC2 project, and more.

What's Popular?

- Color Health Raises \$100M in Series E Round, Plans to Expand Healthcare Services
- Oncology Opportunities Provide 'Pot of Gold at the End of the Double Rainbow' for Illumina
- Invitae Unveils Plans to Expand Cancer Testing Portfolio
- Invitae Q3 Revenues Increase 66 Percent
- Anavasi Diagnostics Awarded \$14.9M NIH Grant for Rapid Molecular SARS-CoV-2 Test

Powered by TREND MD

[About us](#) [Advertise](#) [Contact](#) [FAQ](#) [Jobs](#) [Sitemap](#) [Submit a Tip](#)[Subscribe](#)